文献速递流行病学与生物统计临床试验与 GCP

参与抗癌药物临床试验与生存获益的相关性:系统综述与荟萃分析

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA · 2024-01-01

该研究通过检索PubMed和Embase(2000年1月1日至2022年8月31日)并追溯引文,纳入39篇文献共85项比较,分析试验参与者与常规治疗患者的总生存期。所有研究合并时试验参与者有统计学显著生存获益(HR 0.76,95%CI 0.69-0.82),但按入组标准匹配后获益减弱(HR 0.85,95%CI 0.75-0.97),仅高质量研究合并时获益消失(HR 0.91,95%CI 0.80-1.05),校正发表偏倚后亦消失(HR 0.94,95%CI 0.86-1.03)。

要点

  • 所有研究合并显示试验参与者总生存获益(HR 0.76,95%CI 0.69-0.82)。
  • 按入组标准匹配后生存获益减弱(HR 0.85,95%CI 0.75-0.97)。
  • 仅高质量研究合并时获益消失(HR 0.91,95%CI 0.80-1.05)。

核心结论

  • 许多研究提示癌症试验参与者有生存获益,但在控制重要偏倚和混杂因素的设计中未检测到该获益,高质量研究合并结果与试验参与本身具有有益效应不一致。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase(2000年1月1日至2022年8月31日)并追溯引文,纳入39篇文献共85项试验参与者与常规治疗患者的比较。

主要发现

  • 所有研究合并时试验参与者总生存获益有统计学意义(HR 0.76,95%CI 0.69-0.82)。
  • 按入组标准匹配试验参与者与常规治疗患者的研究亚组中生存获益减弱(HR 0.85,95%CI 0.75-0.97)。
  • 仅合并高质量研究时生存获益消失(HR 0.91,95%CI 0.80-1.05)。
  • 校正潜在发表偏倚后生存获益亦消失(HR 0.94,95%CI 0.86-1.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Many cancer clinical investigators view clinical trials as offering better care for patients than routine clinical care. However, definitive evidence of clinical benefit from trial participation (hereafter referred to as the participation effect) has yet to emerge. OBJECTIVE: To conduct a systematic review and meta-analysis of the evidence examining whether patient participation in cancer trials was associated with greater survival benefit compared with routine care. DATA SOURCES: Studies were found through PubMed and Embase (January 1, 2000, until August 31, 2022), as well as backward and forward citation searching. STUDY SELECTION: Studies were included that compared overall survival of trial participants and routine care patients. DATA EXTRACTION AND SYNTHESIS: Data extraction and methodological quality assessment were completed by 2 independent coders using Covidence software. Data were pooled using a random-effects model and analyzed based on the quality of the comparison between trial participants and routine care patients (ie, extent to which studies controlled for bias and confounders). MAIN OUTCOMES AND MEASURES: The hazard ratio (HR) for overall survival of trial participants vs routine care patients. RESULTS: Thirty-nine publications were included, comprising 85 comparisons of trial participants and routine care patients. The meta-analysis revealed a statistically significant overall survival benefit for trial participants (HR, 0.76 [95% CI, 0.69-0.82]) when all studies were pooled, regardless of design or quality. However, survival benefits diminished in study subsets that matched trial participants and routine care patients for eligibility criteria (HR, 0.85 [95% CI, 0.75-0.97]) and disappeared when only high-quality studies were pooled (HR, 0.91 [95% CI, 0.80-1.05]). They also disappeared when estimates were adjusted for potential publication bias (HR, 0.94 [95% CI, 0.86-1.03]). CONCLUSIONS AND RELEVANCE: Many studies suggest a survival benefit for cancer trial participants. However, these benefits were not detected in studies using designs addressing important sources of bias and confounding. Pooled results of high-quality studies are not consistent with a beneficial effect of trial participation on its own.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Iskander R, Moyer H, Vigneault K, et al. Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-Analysis. JAMA. 2024. PMID: 38767595. doi:10.1001/jama.2024.6281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。